ArticleHepatology communications2021
The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017.
Article in Hepatology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years.Preventive medicine reports · 2025Article
- Stem cells therapies for liver diseases: for current practice and future goals.Hepatology international · 2025Review
- Article
- Liver Disease Increases the Risk of Postoperative Complications in Patients Undergoing Aseptic Revision Total Hip and Knee Arthroplasty.Arthroplasty today · 2024Article
- Food inequity and insecurity and MASLD: burden, challenges, and interventions.Nature reviews. Gastroenterology & hepatology · 2024Review
- Spatial genomics: mapping human steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2024Review
- Assessment of gnostic and stereognostic functions in patients with liver cirrhosis: A comparative study with healthy controls.Journal of back and musculoskeletal rehabilitation · 2024Article
- The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.Hepatology communications · 2024Article
- Increasing prevalence of cirrhosis among insured adults in the United States, 2012-2018.PloS one · 2024Article
- A Beta-Prototype Chatbot for Increasing Health Literacy of Patients With Decompensated Cirrhosis: Usability Study.JMIR human factors · 2023Article
- Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Article
- Article
- Evaluation of treatment access and scope of a multistate hepatitis C virus Extension for Community Healthcare Outcomes telehealth service in the US Indian Health System, 2017-2021.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2023Article
- The effects of moderate alcohol consumption on non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019.Frontiers in public health · 2023Article
- Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach.Clinical and molecular hepatology · 2022Article
- Cutoff Points of Waist Circumference for Predicting Incident Non-Alcoholic Fatty Liver Disease in Middle-Aged and Older Korean Adults.Nutrients · 2022Article
- An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver disease (CLD) causes significant morbidity and mortality in the United States with regional variations. Comparable and consistent state-level measures of CLD-related morbidity and disability among U.S. states have not been well studied. Our aim was to assess the CLD burden within the United States between 2007 and 2017 based on the most common causes of CLD: hepatitis B virus, hepatitis C virus (HCV), alcoholic liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD). The Global Burden of Disease database was used for the years 2007-2017. International Classification of Diseases, Tenth Revision, codes were used to identify liver cancer (LC) and cirrhosis. Disability-adjusted life years (DALYs) were computed by the summation of years of life lost and years lived with disability. All rates reported here were age-standardized rates per 100,000 population. In 2017, there were 167,324 incident CLDs, 21% from LC and 79% from cirrhosis; this number was 30% higher than in 2007. The highest rate increases were seen in Kentucky, New York, and Pennsylvania. In 2017, there were 90,046 CLD-related deaths, which was 34% higher than in 2007. Highest rank increases were seen in Kentucky, Montana, and Washington. The rate of CLD incidence and death due to NAFLD was higher than other causes of CLD. In 2017, CLD caused 2.33 million DALYs, which was 27% higher than in 2007 and was mainly driven by HCV (37.2%), ALD (27.7%), and NAFLD (10.6%). California, Texas, and Florida had the highest DALYs; however, the highest CLD-DALY rates per 100,000 population were seen in New Mexico, District of Columbia, and Oklahoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.